From: Validation of the Clinical COPD Questionnaire (CCQ) in primary care
Clinical COPD | Verified COPD (FEV1/FVC < 0.70**) | |
---|---|---|
Subjects n | 111 | 83 |
Female (%) | 65.8 | 62.7 |
Age years, mean, (range) | 67.1, (42–85) | 67.1, (42–85) |
Smoking habits (%) | ||
Non-smokers | 2.8 | 1.2 |
Ex-smokers | 56.9 | 61.4 |
Smokers | 40.4 | 34.9 |
Missing data | 1.8 | 2.4 |
Disease known since, (%) | ||
< 1 yrs | 19.8 | 10.8 |
1–5 yrs | 37.8 | 39.8 |
> 5 yrs | 42.3 | 49.4 |
BMI, mean, (range) | 24.4, (17–39) | 24.2, (17–39) |
FEV1/FVC ratio – mean (SD), range | 57.8 (14.3), range (26.0–92.6) | 52.4 (11.4), range (26.0–69.0) |
FEV1, % predicted, mean (SD), range | 58.1 (20.2), range (14.8–111.5) | 52.5 (17.9), range (14.8–102.6) |
Severity classification, (%) FEV1 (post bronch. dil.) | ||
FEV1 ≥ 80% predicted | 11.0 | 7.3 |
50% ≤ FEV1 < 80% predicted | 52.3 | 46.3 |
30% ≤ FEV1 < 50% predicted | 30.3 | 37.8 |
FEV1 < 30% predicted | 6.4 | 8.5 |
Medication visit 1 (visit 2)# | ||
- Only SABA or ipratropium as needed (%) | 4.5 (6.5) | 6.1 (6.3) |
- Ipratropium, tiotropium, LABA or SABA as regular medication (%) | 28.2 (26.2) | 26.8 (26.6) |
- Ipratropium, tiotropium, LABA or SABA and ICS as regular medication (%) | 50.0 (50.5 | 54.9 (55.7) |
- ICS without any regular brochodilators (%) | 3.6 (6.5) | 2.4 (5.1) |
- No medication (%) | 13.6 (10.3) | 9.8 (6.3) |
- Missing data (n) | 1 (4) | 1 (4) |